A Randomized Double-blind Study to Assess the Safety and Efficacy of EDP-305 in Subjects With Liver-biopsy Proven NASH

  • STATUS
    Recruiting
  • participants needed
    336
  • sponsor
    Enanta Pharmaceuticals
Updated on 7 February 2023
vasectomy
body mass index
fatty liver
steatosis
fibrosis

Summary

A randomized, double-blind study to assess the safety and efficacy of EDP-305 in subjects with liver-biopsy proven Non-Alcoholic Steatohepatitis (NASH)

Details
Condition Non Alcoholic Steatohepatitis
Treatment Placebo, EDP-305 1.5 mg, EDP-305 2 mg
Clinical Study IdentifierNCT04378010
SponsorEnanta Pharmaceuticals
Last Modified on7 February 2023

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note